These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6334064)

  • 1. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
    Trouillas P
    Ital J Neurol Sci; 1984 Sep; 5(3):253-66. PubMed ID: 6334064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
    Trouillas P; Garde A; Robert JM; Renaud B; Adeleine P; Bard J; Brudon F
    Rev Neurol (Paris); 1982; 138(5):415-35. PubMed ID: 6983101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
    Trouillas P; Garde A; Robert JM; Adeleine P
    C R Seances Acad Sci III; 1981 Jan; 292(1):119-22. PubMed ID: 6786764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases.
    Wessel K; Hermsdörfer J; Deger K; Herzog T; Huss GP; Kömpf D; Mai N; Schimrigk K; Wittkämper A; Ziegler W
    Arch Neurol; 1995 May; 52(5):451-5. PubMed ID: 7733838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels.
    Young SN; Gauthier S; Chouinard G; Anderson GM; Purdy WC
    J Neural Transm; 1982; 53(1):83-7. PubMed ID: 6801200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders.
    Klein P; Lees A; Stern G
    Adv Neurol; 1987; 45():603-4. PubMed ID: 3493632
    [No Abstract]   [Full Text] [Related]  

  • 7. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebeller ataxia.
    Trouillas P
    Arch Neurol; 1990 Jan; 47(1):12. PubMed ID: 2403786
    [No Abstract]   [Full Text] [Related]  

  • 9. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study.
    Trouillas P; Serratrice G; Laplane D; Rascol A; Augustin P; Barroche G; Clanet M; Degos CF; Desnuelle C; Dumas R
    Arch Neurol; 1995 May; 52(5):456-60. PubMed ID: 7733839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing.
    Trouillas P; Brudon F; Adeleine P
    Arch Neurol; 1988 Nov; 45(11):1217-22. PubMed ID: 3190503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.
    Beretta E; Regli F; de Crousaz G; Steck AJ
    J Neurol; 1981; 225(1):57-62. PubMed ID: 6164757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
    Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lecithin therapy of hereditary ataxia].
    Trizio M; Pozio G; Margari L; Massagli A; Serlenga L
    Riv Patol Nerv Ment; 1983; 104(2):49-59. PubMed ID: 6679921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hereditary ataxia].
    Radojicić BM
    Med Glas; 1972 Aug; 26(8):271-7. PubMed ID: 4121021
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy: failure of L-hydroxytryptophan to improve cerebellar ataxia.
    Manto M; Hildebrand J; Godaux E; Roland H; Blum S; Jacquy J
    Arch Neurol; 1997 Oct; 54(10):1192-4. PubMed ID: 9341562
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of the discriminative stimulus properties of l-5-hydroxytryptophan in the presence of either citalopram or Ro 4-4602.
    Winter JC; Rabin RA
    Pharmacol Biochem Behav; 1988 Jul; 30(3):613-6. PubMed ID: 3264918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
    Zmilacher K; Battegay R; Gastpar M
    Neuropsychobiology; 1988; 20(1):28-35. PubMed ID: 3265988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cerebellar serotoninergic system and its possible involvement in cerebellar ataxia.
    Trouillas P
    Can J Neurol Sci; 1993 May; 20 Suppl 3():S78-82. PubMed ID: 8334597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unexpected effect of L-5 hydroxytryptophan-ethyl-ester combined with a peripheral decarboxylase inhibitor on human serum prolactin.
    van Praag HM; Korf J; Lequin RM
    Psychopharmacol Commun; 1976; 2(5-6):369-78. PubMed ID: 1088302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiology and clinical polymorphism of hereditary ataxia].
    Shutov AA; Dedik GK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1978; 78(6):825-30. PubMed ID: 676607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.